IRTC
iRhythm Technologies, Inc. · Healthcare · Medical - Devices
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 104 | -6 | 23.67M | $2.82B | +4 | −9 |
| Q1 2026 | 112 | +1 | 25.32M | $2.99B | +11 | −11 |
| Q4 2025 | 110 | -1 | 25.32M | $4.49B | +2 | −2 |
| Q3 2025 | 21 | +1 | 12.24M | $2.10B | +1 | — |
| Q2 2025 | 17 | +4 | 9.71M | $1.50B | +4 | — |
| Q1 2025 | 10 | +1 | 2.81M | $294.19M | +2 | −1 |
| Q4 2024 | 9 | -1 | 2.41M | $217.31M | +2 | −3 |
| Q3 2024 | 9 | +1 | 1.67M | $124.10M | +2 | −1 |
| Q2 2024 | 8 | — | 2.43M | $261.78M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 727.88K | — | $78.36M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Point72 Asset Management ✦ | 536.20K | — | $57.72M | 0.2% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 495.98K | — | $53.39M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 216.76K | — | $23.33M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Wellington Management ✦ | 201.47K | — | $21.69M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 164.19K | — | $17.67M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Norges Bank ✦ (passive) | 83.93K | — | $9.03M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Bridgewater Associates ✦ | 5.49K | — | $590,513 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 300 holders, 34.72M shares, $4.07B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 26.86K sh · $3.35M
Officer · 7.09K sh · $884,156
Officer · 7.09K sh · $884,170
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology